Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.
Lisa Salvatore
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Francesca Bergamo
No relevant relationships to disclose
Antonella Galiano
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Laura Ferrari
No relevant relationships to disclose
Elena Ongaro
No relevant relationships to disclose
Giovanni Cardellino
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Sara Lucchesi
No relevant relationships to disclose
Maria Banzi
No relevant relationships to disclose
Andrea Ciarlo
No relevant relationships to disclose
Emanuela Miraglio
No relevant relationships to disclose
Sara Delfanti
No relevant relationships to disclose
Domenico C. Corsi
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi
Honoraria - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi
Research Funding - Amgen; Bayer; Lilly; Merck Serono; Roche; Sanofi